These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37026971)

  • 1. The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review.
    Xue F; Liu X; Qi X; Zhou J; Liu Y
    Adv Clin Exp Med; 2023 Jun; 32(6):701-706. PubMed ID: 37026971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
    Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
    Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
    Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
    Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
    Rapoport BL; Jordan K; Weinstein C
    Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
    Van Belle SJ; Cocquyt V
    Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
    Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
    BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.
    Li Y; Wan Y; Yang X; Chen P; Gui Y; He L; Xie Y; Tian J; Duan P; Liu G; Sun Y; Zhu J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):290. PubMed ID: 38836908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
    Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
    Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
    Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
    Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
    Zhao Y; Zhao B; Chen G; Chen Y; Liao Z; Zhang H; Feng W; Li Y; Weng H; Li W; Zhou Y; Ren B; Lu Y; Chen J; Liu Z; Su Z; Wang W; Zhang L
    Cancer Commun (Lond); 2023 Feb; 43(2):246-256. PubMed ID: 36545810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients.
    Dranitsaris G; Moezi M; Dobson K; Phelan R; Blau S
    Support Care Cancer; 2022 Aug; 30(8):6649-6658. PubMed ID: 35499619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
    Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
    Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.